Drug intelligence / Profile preview

NimoVent

Development stage: Preclinical
Lead developer: PDS Biotech
Modality: Small Molecules
Administration: Intraventricular

Overview

**NimoVent** is a novel formulation of the calcium channel blocker **nimodipine** developed by Edge Therapeutics for administration via external ventricular drainage (EVD) tubes in patients following subarachnoid hemorrhage or brain surgery. Nimodipine selectively inhibits L-type voltage-gated calcium channels in vascular smooth muscle, preferentially dilating cerebral arteries to improve collateral blood flow, reduce ischemic deficits, and prevent neuronal calcium overload. This targeted delivery approach aims to enhance efficacy while minimizing systemic exposure compared to oral or intravenous forms, with development focused on safety, toxicity studies, and Phase IIa dose escalation trials as of 2011.[8]

Brand names: NimoVent

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on NimoVent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NimoVent.

Explore the full profile